论文部分内容阅读
随机选取慢性乙肝患者104例,按治疗时间平均分为A、B两组。A组患者给予阿德福韦酯治疗,B组患者给予阿德福韦酯联合免疫调节剂治疗,对比两组患者临床治疗效果。结果 A组患者治疗总有效率为77.0%,B组患者治疗总有效率为96.2%,B组患者临床治疗效果优于A组,差异显著,具有统计学意义(P<0.05)。两组患者在治疗期间均未出现明显不良反应。阿德福韦酯联合免疫调节剂治疗慢性乙肝的效果显著,值得临床推广与应用。
Randomly selected 104 cases of chronic hepatitis B patients, according to the average treatment time is divided into A, B two groups. A group of patients given adefovir dipivoxil treatment, B group were given adefovir dipivoxil combined with immunomodulatory agents, compared the clinical efficacy of two groups of patients. Results The total effective rate was 77.0% in group A and 96.2% in group B, and the clinical effect in group B was better than that in group A (P <0.05). No significant adverse reactions occurred in both groups during the treatment. Adefovir dipivoxil combined with immunomodulatory agents for the treatment of chronic hepatitis B effect is significant, worthy of clinical promotion and application.